- Home
- SCNI vs VBIO Comparison
SCNI vs VBIO Comparison
Compare SCNI & VBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCNI | VBIO |
|---|---|---|
| Founded | 2003 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4M | 1.6M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SCNI | VBIO |
|---|---|---|
| Price | $2.75 | $0.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 512.5K | ★ 22.2M |
| Earning Date | 05-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $780,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.21 | $0.11 |
| 52 Week High | $3.58 | $1.30 |
Technical Indicators
Market Signals| Indicator | SCNI | VBIO |
|---|---|---|
| Relative Strength Index (RSI) | 85.71 | 47.54 |
| Support Level | $0.40 | N/A |
| Resistance Level | N/A | $0.48 |
| Average True Range (ATR) | 0.15 | 0.44 |
| MACD | 0.31 | 0.07 |
| Stochastic Oscillator | 77.97 | 0.93 |
Price Performance
Historical ComparisonAbout SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.
About VBIO Valion Bio Inc. Common Stock
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.